September 8, 2021

Bridging the Gap: Disparities in Heart Failure Associated with T2D: An Opportunity to Improve Care in the African-American Community

Registration coming soon

November 10, 2021

Overview of Therapeutic Options in the Treatment of NASH/NAFLD

Registration coming soon

Impact of COVID-19 and New Treatment Approaches

Originally presented on April 7, 2021 by Rachelle Richner, MSN, CRNP, NP-C and Julia Blanchette, PhD, RN, CDCES

This timely webinar will give an overview of what we know about the COVID-19 disease state, including pathophysiology and signs and symptoms. We'll profile high risk patient groups and how to address risk mitigation within these groups. And finally, we look at COVID-19 vaccines: what vaccines are currently available and what's coming; vaccine development and currently approved treatments; efficacy, dosing, and storage options for each vaccine; and a review of data from recent studies.

Upon completion of this activity, participants will be able to:

1. Understand the basics of COVID-19 in a rapidly changing environment
2. Discuss the national and international impact of COVID-19
3. Explore patient groups at high-risk for COVID-19
4. Discuss risk mitigation strategies for individuals
5. Discuss new treatment methods, vaccine development, and guideline-recommended therapy

Guideline Updates in the Management of People with Type 2 Diabetes and Implications to Patient Care

Originally presented on June 9, 2021 by Ted Okerson, MD, FACP, FACE, FTOS; Paul Tomasic, MD, MS, FACP, FACE; Davida F. Kruger, MSN, APN-BC, BC-ADM; and Curtis Triplitt, PharmD, CDCES

Hear from a variety of expert panelists on the most recent guideline updates and practical guidance for patient care. Understand some of the nuances of guideline recommendations based on data from recent clinical trials and outcomes studies.

Upon completion of this activity, participants will be able to:

1. Become familiar with evidence from recent landmark CVOTs (cardiovascular outcome trials) and updated guidelines to help appropriately individualize the management of people with type 2 diabetes.
2. Understand new treatment pathways based on CV risk assessment of people with type 2 diabetes
3. Recognize the need to manage CV risk factors within the paradigm of the overall management of type 2 diabetes and associated macrovascular complications.